HUMA Form 4: Brady Dougan-controlled entity disposes 2.24M shares
Rhea-AI Filing Summary
Brady W. Dougan, a director of Humacyte, Inc. (HUMA), reported sales of common stock executed by Ayabudge LLC, an entity he controls. Between 08/18/2025 and 08/20/2025 Ayabudge sold a total of 2,241,045 shares in multiple transactions at weighted average prices of $1.83, $1.63 and $1.58 per share (per-footnote ranges: $1.79–$1.92, $1.57–$1.76, $1.53–$1.69). After the reported transactions Ayabudge beneficially owned 0 shares. The filing shows Mr. Dougan retains indirect beneficial ownership of 243,851 shares through his spouse and 1,148,240 shares through The Niklason Living Trust.
Positive
- Disclosure includes weighted average prices and price ranges for each day's sales, and an offer to provide detailed breakdowns on request
- Explanation of use of proceeds is provided: sales were used to pay down leverage and provide liquidity when the issuer had no financing
Negative
- Substantial disposition: Ayabudge LLC sold a total of 2,241,045 shares, reducing its beneficial ownership to 0 shares
- Limited price granularity: Form 4 supplies only weighted average prices and ranges, not per-transaction quantities at each price
Insights
TL;DR Director-controlled entity sold 2,241,045 HUMA shares over three days; reporting shows Ayabudge now holds zero shares.
The reported Form 4 discloses concentrated dispositions by Ayabudge LLC under Mr. Dougan's control totaling 2,241,045 shares across 08/18/2025–08/20/2025. The filing provides weighted average prices and footnote price ranges for each day but does not break out per-transaction quantities by price. Post-transaction holdings indicate Ayabudge no longer beneficially owns shares while Mr. Dougan retains indirect stakes via spouse (243,851 shares) and The Niklason Living Trust (1,148,240 shares). The disclosure states proceeds were used to pay down leverage and to permit secondary liquidity when the issuer had no financing underway.
TL;DR Reported sales were executed by a controlled entity; director still holds material indirect positions through family/trust vehicles.
The Form 4 confirms the transactions were executed by Ayabudge LLC, controlled by the reporting person, and includes explanatory footnotes describing purpose and pricing ranges. The filing is procedural and compliant in form: it identifies relationship (Director), method of sale, and provides a commitment to furnish detailed price-by-price information on request. It does not disclose any agreements with the issuer or changes to board or officer status.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 591,685 | $1.58 | $935K |
| Sale | Common Stock | 1,100,000 | $1.63 | $1.79M |
| Sale | Common Stock | 549,360 | $1.83 | $1.01M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.79 to $1.92. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.57 to $1.76. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.53 to $1.69. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
